Press Releases News Year None202020192018201720162015201420132012 IVERIC bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019 Sep 04, 2019 | IVERIC bio to Present at the Wedbush PacGrow Healthcare Conference Aug 07, 2019 | IVERIC bio Reports Second Quarter 2019 Financial and Operating Results Aug 01, 2019 | IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 | IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 | IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases Jun 17, 2019 | IVERIC bio Reports First Quarter 2019 Financial and Operating Results May 08, 2019 | IVERIC bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019 May 01, 2019 | Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio Apr 16, 2019 | Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases Apr 11, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 |
IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 |
IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases Jun 17, 2019 |
IVERIC bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019 May 01, 2019 |
Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio Apr 16, 2019 |
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases Apr 11, 2019 |
Press Releases News Year None202020192018201720162015201420132012 IVERIC bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019 Sep 04, 2019 | IVERIC bio to Present at the Wedbush PacGrow Healthcare Conference Aug 07, 2019 | IVERIC bio Reports Second Quarter 2019 Financial and Operating Results Aug 01, 2019 | IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 | IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 | IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases Jun 17, 2019 | IVERIC bio Reports First Quarter 2019 Financial and Operating Results May 08, 2019 | IVERIC bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019 May 01, 2019 | Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio Apr 16, 2019 | Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases Apr 11, 2019 | Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Report Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 Jul 25, 2019 |
IVERIC bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapy Portfolio with USH2A-Related Inherited Retinal Diseases Program Jul 23, 2019 |
IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases Jun 17, 2019 |
IVERIC bio to Report First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019 May 01, 2019 |
Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio Apr 16, 2019 |
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases Apr 11, 2019 |
